Portal de Periódicos da CAPES

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

2013; Elsevier BV; Volume: 24; Issue: 9 Linguagem: Inglês

10.1093/annonc/mdt231

1569-8041

Stefan Kubicka, Richard Greil, Thierry André, Jaafar Bennouna, Javier Sastre, Eric Van Cutsem, Roger von Moos, Pia Österlund, Irmarie Reyes‐Rivera, Thomas Müller, Martina Makrutzki, Dirk Arnold, Johannes Andel, P Balcke, B. Benedicic, W. Eisterer, Michael Fridrik, Björn Jagdt, Felix Keil, A. Kretschmer, Peter Krippl, Horst Oexle, Martin Pecherstorfer, H. Samonigg, Matthias Schmid, J. Thaler, Christoph Tinchon, Hannah Weiss, Janine Arts, Marc De Man, G Demolin, Jos Janssens, Marc Polus, B. Benczikova, Bohuslav Melichar, Jana Prausová, Pavel Vítek, Fahimeh Andersen, Brita B. Jensen, Nina Keldsen, Kell Østerlind, Kirsten Vistisen, Anneli Elme, Agnes Mägi, Kristiina Ojamaa, R. Ristamäki, Tapio Salminen, Méher Ben Abdelghani, O. Bouché, Christophe Borg, Karine Bouhier‐Leporrier, G. Breysacher, Laurence Choné, M.-C. Clavero Fabri, G. Deplanque, Françoise Desseigne, L.-M. Dourthe, J. Ezenfis, R. Faroux, E. François, C Garnier, M Gaspard, Mohamed Hebbar, J.F. Illory, Marie‐Christine Kaminsky, Thierry Lecomte, J. Legoux, B. Levaché, Camille Lobry, JP Lotz, May Mabro, Sophie Manet-Lacombe, S. Manfredi, T. Matysiak Budnik, Laurent Miglianico, L. Mineur, Isabelle Moullet, H. Naman, P. Nouyrigat, Sandrine Oziel-Taïeb, H. Perrier, D. Pezet, Jennifer Philip, V. Pottier, M. Porneuf, M Ramdani, Daniel Ré, Y. Rinaldi, D. Spaeth, Julien Taı̈eb, E. Terrebonne, Patrick Texereau, Anne Thirot Bidault, C. Tournigand, N. Tubiana-Mathieu, J Vantelon, F. Viret, Marc Ychou, Markus Bangerter, Markus Bertram, B Bohnsteen, L. Brinkmann, K Caca, C. Constantin, Hans-Jörg Cordes, G. Dietrich, Jochen Eggert, Erik Engel, J. Fahlke, H Fensterer, A. Florschütz, Gunnar Folprecht, H. Forstbauer, W. Freier, Malika Freund, N. Frickhofen, E Gäbele, Michael Geißler, Frank Gieseler, Thomas Göhler, U. Graeven, Matthias Groschek, Marc Grundeis, Ulrich Hacker, Volker Hagen, Holger Hebart, S. Hegewisch-Becker, Michael Heike, Thomas Herrmann, Barbara Hildebrandt, H.‐G. Höffkes, G. Hübner, Jutta Hübner, E. Kettner, Michael Kneba, Joern Kohnke, G. Kojouharoff, Christian König, Albrecht Kretzschmar, H. Kröning, K. Kürner, Frank Lammert, Christian Lerchenmüller, A. Lück, Jens Meiler, H.‐G. Mergenthaler, Lutz Müller, C. Müller-Naendrup, Arnd Nusch, J Papke, Rainer Porschen, J Rädle, Christina Peveling genannt Reddemann, K. Ridwelski, J Riera-Knorrenschild, Jochen Rudi, A. Schmalenberger, Carl C. Schimanski, Frank Schlegel, C. Schlichting, P. H. Schmidt, Wolff Schmiegel, Stephanie Schmitz, Henning Schulze‐Bergkamen, I. Schwaner, A. Schwarzer, Michael Schwerdtfeger, Johannes Selbach, M. Sieber, Jürgen Siebler, Peter Staib, Martina Stauch, Claus-Christoph Steffens, P. Stübs, Jens J. W. Tischendorf, T. Trarbach, Dirk Tummes, Anette R. Valdix, Arndt Vogel, G. Wichert, Matthias Walther, W. Welslau, G. Wilhelm, H. Wobster, Timo Wolf, N. Zeigenhagen, B. Zomorodbaksch, Erdogan Batman, Haiko J. Bloemendal, Diederik F.S. Kehrer, Tormod K. Guren, G. Indrebø, Christian Kersten, H. Soerbye, Maria Candida Barisson Villares Fragoso, R Fragoso, Juan Carlos Mellidez, A. Sa, ABDULRAHMAN A. AL-JOBRAN, Tarek Darwish, Vicente Alonso-Orduña, Jorge Aparicio, Enrique Aranda, C. Bosch, A. Galán-Brotons, I. Busquier Hernandez, Juan Carlos Cámara, J.M. Campos Cervera, Cathy Giron, P. Martýnez del Prado, O. Donnay, P. Escudero, E. Falco, Javier Gállego, Pilar Alfonso, E. González, Cristina Grávalos, R. Guardeño, A. Juárez, A. López Ladrón, F. Losa Gaspà, J Verge, E. Gaspar, B. Massuti Sureda, José A. Pérez‐Molina, Inés Cabezas Montero, Adelaida Lacasta Muñoa, Maria Naranjo, MA Jiménez Moreno, Vanessa Pachón Olmos, Carles Pericay, Juan José Reina Zoilo, Fernando Rivera, Ana Ruiz‐Casado, M.J. Safont, Antonieta Salud Salvia, M. Tobeña, J.C. Toral, Vicente Valentí, Manuel Valladares Ayerbes, José María Viéitez, Ruth Vera, José María Viéitez, A. Berglund, Eva Fernebro, V. Hess-Umbricht, M. Pless, Răzvan Popescu, Sun Young Rha,

Gastric Cancer Management and Outcomes

BackgroundML18147 evaluated continued bevacizumab with second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) progressing after the standard first-line bevacizumab-containing therapy.Patients and methodsEvaluating outcomes according to tumor Kirsten rat sarcoma virus oncogene (KRAS) status was an exploratory analysis. KRAS data were collected from local laboratories (using their established methods) and/or from a central laboratory (mutation-specific Scorpion amplification-refractory mutation system). No adjustment was made for multiplicity; analyses were not powered to detect statistically significant differences.ResultsOf 820 patients, 616 (75%) had unambiguous KRAS data; 316 (51%) had KRAS wild-type tumors and 300 (49%) had mutant KRAS tumors. The median progression-free survival (PFS) was 6.4 months for bevacizumab plus chemotherapy and 4.5 months for chemotherapy [P < 0.0001; HR = 0.61; 95% confidence interval (CI): 0.49–0.77] for wild-type KRAS and 5.5 and 4.1 months, respectively (P = 0.0027; HR = 0.70; 95% CI: 0.56–0.89) for mutant KRAS. The median overall survival (OS) was 15.4 and 11.1 months, respectively (P = 0.0052; HR = 0.69; 95% CI: 0.53–0.90) for wild-type KRAS and 10.4 versus 10.0 months, respectively (P = 0.4969; HR = 0.92; 95% CI: 0.71–1.18) for mutant KRAS. In both analyses, no treatment interaction by KRAS status was observed (PFS, P = 0.4436; OS, P = 0.1266).ConclusionsBevacizumab beyond first progression represents an option for patients with mCRC treated with bevacizumab plus standard first-line chemotherapy, independent of KRAS status.